Viking Therapeutics, Inc. (Viking) , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the publication of ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH ...
Indian Defence Review on MSN
This Microbe Just Broke a Rule of Biology Scientists Thought Was Unbreakable
Scientists have identified a microbe capable of interpreting a single piece of genetic code in two completely different ways.
Incregen Therapeutics Advances First-in-Class GIP Ligand Antagonist INC-118 into IND-Enabling Development to Address Long-Term Obesity Management INC-118 directly antagonizes the circulating Glucose ...
With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...
From the King Kong of weight-loss jabs to the Godzilla of the category, the GLP-1 industry is undergoing big changes ...
Nausea is the most common tirzepatide side effect. In Zepbound clinical trials, 25 to 28 percent of people reported nausea. Tirzepatide might cause nausea because it ...
Vitamin C isn't just for the daytime. Here's a popular night cream that uses the star ingredient to help fade dark spots ...
Up until recently, all three GLP-1 drugs for weight loss were only available in injectable form. However, the FDA approved ...
The SURMOUNT-1 trial (tirzepatide, published in NEJM 2022) demonstrated that participants with obesity or overweight without diabetes who received tirzepatide experienced weight reductions of 16.0% ...
In men with type 1 diabetes, intravenous glucose-dependent insulinotropic polypeptide can reduce postprandial plasma glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback